Pulmonology

This analysis may help to inform research evaluating the value of obstructive sleep apnea treatments designed to minimize cardiovascular risk as well as related deaths among older patients.

A phase 3 trial found mirtazapine ineffective in reducing breathlessness in respiratory disease patients, urging caution with off-label antidepressant use.

These data on depemokimab, a long-acting asthma treatment, suggest the medication reduces serious attacks by more than half and strongly reduces asthma exacerbations.

The Delphi survey collected opinions from members of the European Alpha-1 Research Collaboration to guide the diagnosis, treatment, and management of severe AATD.

This Month in Review summarizes some of the most significant stories covered in the month of August in the pulmonary health space, including new research and FDA news.

During this segment of a recent Lungcast, Mora and Sadeameli speak about 2 key topics: vaping and e-cigarette use among children as well as vaccinations and related misinformation.

Heat-related mortality rates in the US notably grew between 1999 and 2023, particularly since 2016.

Although the study concluded AI had equal or lower rates of critical misses than radiology reports of remarkable chest radiographs, AI had greater critical miss rates.

On August 19, 2024, Liquidia Corporation announced the FDA's tentative approval of treprostinil inhalation powder for adults with PAH and PH-ILD.

Mora and Sadreameli join Lungcast to provide a back-to-school health blueprint, including topics like rescue inhalers, vaccination, vaping and air quality.

The FDA approved epinephrine nasal spray (Neffy) for the emergency treatment of allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh at least 30 kg.

On August 6, 2024, the FDA warned against using unapproved inhalant products marketed for alertness and energy, citing reports of adverse events including seizures and fainting.

Pneumonia misdiagnoses are common, with one-third of pneumonia diagnoses changing from hospital admission to discharge, a study found.

Strnad explains how findings from the SEQUOIA study inform fazirsiran’s use in patients with AATD-associated liver disease and its further evaluation in future phase 3 trials.

This segment of the latest Lungcast featured a discussion about heat and its interplay with various types of common medications.

This review of major news in pulmonology from July highlights an FDA decision regarding treatment for vaping dependence, prenatal pollution exposure’s impact on asthma, and more.

In this Lungcast segment, Bludorn speaks on commonly-seen heat-related illnesses amid a changing climate as well as how to screen for related risks.

This designation was based on the ORCA-V1 trial’s phase 2 findings indicating that cytisinicline more than doubled patients’ odds of e-cigarette cessation versus placebo.

Greater circulating Z-polymer levels were associated with an increased risk of adverse clinical outcomes in adults with AATD and the PiZZ genotype.

These data highlighted the association of moderate air pollution exposure during pregnancy, infancy, and early childhood on pulmonary function at school age.

The homogenous genotyping test combines allele-specific tailed primers with SYBR-Green to facilitate fast and accurate detection of PI*S and PI*Z alleles of SERPINA1.

Bludorn joins Lungcast to review the increasing effects and signs of heat-related illness amid record-high temperatures.

New research presented at ASRS 2024 links maternal asthma to a higher risk of advanced retinopathy of prematurity.

Findings from a phase 2b study demonstrate fazirsiran’s dose-dependent impact on Z-AAT concentrations and histological measures of liver disease in patients with AATD.

In this summary of major news in pulmonology covered in June 2024, approvals by the FDA, new episodes of Lungcast, news on COPD, and more are highlighted.